<DOC>
	<DOCNO>NCT02558465</DOCNO>
	<brief_summary>The objective investigation ass safety effectiveness Xarelto practice routine use VTE secondary prevention acute DVT , focus hemorrhagic-related AEs , recurrent venous thromboembolism ( PE/DVT ) , all-cause mortality . This study company sponsor , one- arm prospective cohort study patient Rivaroxaban treatment VTE ( PE/DVT ) chosen . The study include standard observation period ( 1 year ) extension survey period ( 2 year , long ) .</brief_summary>
	<brief_title>Special Drug Use Investigation Xarelto Venous Thromboembolism ( VTE )</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Patients start rivaroxaban VTE ( pulmonary embolism , deep vein thrombosis ) anticoagulation therapy Patients contraindicate base product label already receive Xarelto treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Xarelto , rivaroxaban , VTE , PE , DVT , Japan , PMS , SDUI</keyword>
</DOC>